Analytical Data
-
基因名
PDL1
- Application
-
别名
PDL1；B7H1；PDCD1L1；PDCD1LG1；Programmed cell death 1 ligand 1
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9NZQ7
-
表达区间
19-238aa
-
氨基酸序列
FTVTVPKDLY VVEYGSNMTI ECKFPVEKQL DLAALIVYWE MEDKNIIQFV HGEEDLKVQH SSYRQRARLL KDQLSLGNAA LQITDVKLQD AGVYRCMISY GGADYKRITV KVNAPYNKIN QRILVVDPVT SEHELTCQAE GYPKAEVIWT SSDHQVLSGK TTTTNSKREE KLFNVTSTLR INTTTNEIFY CTFRRLDPEE NHTAELVIPE LPLAHPPNER
-
分子量
25 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Programmed death-ligand 1 (PD-L1) is a crucial immune checkpoint protein that plays a significant role in the regulation of immune responses, particularly in the context of cancer. By interacting with its receptor, PD-1, PD-L1 inhibits T-cell activation and promotes immune tolerance, allowing tumors to evade immune detection. The dysregulation of PD-L1 expression is associated with various cancers, leading to the development of immune checkpoint inhibitors that block this interaction and enhance anti-tumor immunity. Research on recombinant PD-L1 proteins has gained momentum as these proteins serve as valuable tools for understanding the biology of the PD-1/PD-L1 pathway, developing novel therapeutic strategies, and generating specific antibodies. Additionally, recombinant PD-L1 proteins can be used in vaccine formulations to stimulate immune responses against tumors expressing PD-L1. The ongoing exploration of PD-L1 as a therapeutic target has not only reshaped cancer immunotherapy but has also provided insights into the broader mechanisms of immune regulation and potential applications in autoimmune diseases. As our understanding of PD-L1 biology evolves, the development of sophisticated recombinant proteins and their applications in both diagnostic and therapeutic contexts will continue to be a vital area of research in oncology and immunology.
